(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 December 2019 (19.12.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/238904 A1

(51) International Patent Classification:
A61K 9/10 (2006.01) *A61K 31/519* (2006.01)
A61K 47/10 (2017.01) *A61P 35/00* (2006.01)
A61K 47/38 (2006.01) *A61P 35/02* (2006.01)

(21) International Application Number:
PCT/EP2019/065637

(22) International Filing Date:
14 June 2019 (14.06.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
18177987.7 15 June 2018 (15.06.2018) EP

(71) Applicant: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventors: **BERNINI, Maristella**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **DONG, Wenyu**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **HOLM, René**; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE).

(74) Agent: **PUREWAL, Savroop**; J&J Patent Law Department Turnhoutseweg, 30 Turnhoutseweg 30, 2340 Beerse (BE).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: FORMULATIONS/COMPOSITIONS COMPRISING IBRUTINIB



(I)

(57) Abstract: Disclosed are formulations/compositions comprising ibrutinib: (I) as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.

WO 2019/238904 A1